	US 12,410,394 B2
	Composition comprising nicotinamide mononucleotide and leucomethylene blue
Joseph Chalifoux, Nashua, NH (US)
Assigned to Athergen, Inc., Dover, DE (US)
Filed by Athergen, Inc., Dover, DE (US)
Filed on Jan. 6, 2023, as Appl. No. 18/093,860.
Prior Publication US 2024/0228949 A1, Jul. 11, 2024
Int. Cl. C12N 5/00 (2006.01); C12N 5/074 (2010.01); C12N 15/86 (2006.01)

CPC C12N 5/0018 (2013.01) [C12N 5/0607 (2013.01); C12N 15/86 (2013.01); C12N 2500/40 (2013.01); C12N 2501/60 (2013.01)]

10 Claims

1. A composition comprising:

a base molecule;

a combination of nicotinamide mononucleotide and leucomethylene blue, wherein the combination comprises aqueous leucomethylene blue-nicotinamide mononucleotide version 1 (AqLNMNol);

a combination of trichostatin A and aqueous leucomethylene blue-nicotinamide mononucleotide version 1, wherein the combination comprises aqueous leucomethylene blue-nicotinamide mononucleotide version 2 (AqLNMNo2); and

zwitterionic liposomes.